B. BRAUN MIDAZOLAM midazolam (as hydrochloride) 5 mg/5 mL Solution for Injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun midazolam midazolam (as hydrochloride) 5 mg/5 ml solution for injection ampoule

b braun australia pty ltd - midazolam hydrochloride, quantity: 1.112 mg/ml (equivalent: midazolam, qty 1 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time; iv for sedation in intensive care units; intermittent administration or continuous infusion; im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

B. BRAUN MIDAZOLAM midazolam (as hydrochloride) 5 mg/1 mL Solution for Injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun midazolam midazolam (as hydrochloride) 5 mg/1 ml solution for injection ampoule

b braun australia pty ltd - midazolam hydrochloride, quantity: 5.56 mg/ml (equivalent: midazolam, qty 5 mg/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time; iv for sedation in intensive care units; intermittent administration or continuous infusion; im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

B. BRAUN MIDAZOLAM midazolam (as hydrochloride) 15 mg/3 mL Solution for Injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

b. braun midazolam midazolam (as hydrochloride) 15 mg/3 ml solution for injection ampoule

b braun australia pty ltd - midazolam hydrochloride, quantity: 5.56 mg/ml (equivalent: midazolam, qty 5 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time; iv for sedation in intensive care units; intermittent administration or continuous infusion; im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

SIGNIFOR pasireotide 900 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 900 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 1128.6 microgram (equivalent: pasireotide, qty 900 microgram) - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; tartaric acid - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR pasireotide 300 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 300 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 376.2 microgram (equivalent: pasireotide, qty microgram) - injection, solution - excipient ingredients: water for injections; mannitol; tartaric acid; sodium hydroxide - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

SIGNIFOR pasireotide 600 microgram/1 mL (as diaspartate) solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

signifor pasireotide 600 microgram/1 ml (as diaspartate) solution for injection ampoule

recordati rare diseases australia pty ltd - pasireotide diaspartate, quantity: 752.4 microgram (equivalent: pasireotide, qty 600 microgram) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; tartaric acid; mannitol - the treatment of adult patients with cushing?s disease for whom surgery is not an option or for whom surgery has failed.

Oxycodone Juno oxycodone hydrochloride 200 mg / 20 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 200 mg / 20 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Oxycodone Juno oxycodone hydrochloride 20 mg / 2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 20 mg / 2 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Oxycodone Juno oxycodone hydrochloride 10 mg / 1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone juno oxycodone hydrochloride 10 mg / 1 ml solution for injection ampoule

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

OXYCODONE WKT oxycodone hydrochloride 20 mg/2 ml solution for injection or infusion, glass ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone wkt oxycodone hydrochloride 20 mg/2 ml solution for injection or infusion, glass ampoules

wockhardt bio pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; sodium hydroxide; water for injections; sodium chloride; sodium citrate; hydrochloric acid - oxycodone wkt is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.